bms-986166
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 28, 2016 (NCT02790125)
Timeline
Indications
Mechanism of action
- Sphingosine 1-phosphate receptor 1MODULATOR
S1PR1 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bms-986166
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05409157 | Phase 1 | Jun 17, 2022 | Bristol-Myers Squibb |
| NCT05014438 | Phase 2 | Aug 16, 2021 | Bristol-Myers Squibb |
| NCT04934696 | Phase 1 | Aug 3, 2021 | Bristol-Myers Squibb |
| NCT04956627 | Phase 1 | Jul 28, 2021 | Bristol-Myers Squibb |
| NCT04965402 | Phase 1 | Jul 9, 2021 | Bristol-Myers Squibb |
| NCT03038711 | Phase 1 | Feb 1, 2017 | Bristol-Myers Squibb |
| NCT02790125 | Phase 1 | Jul 28, 2016 | Bristol-Myers Squibb |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 7 | 7 | 2 | 2016 |
1 organizations
Page 1 / 1